PhaseV raises $15M to optimize clinical trials with conventional machine learning | CTech

PhaseV, which develops causal machine learning (ML) technology that optimizes clinical trial design and analysis, announced Tuesday that it has raised $15 million in funding led by Viola Ventures and Exor Ventures, including participation from LionBird and a group of has gathered prominent angel investors. .

A recent Deloitte study estimated the average cost of developing a new drug at $2.3 billion in 2022, with an average time of 7.1 years. Furthermore, the vast majority of drug applicants do not make it to the finish line, and many fail in the clinical phase even if the biologic works. The PhaseVs platform provides clinical development teams with an advanced ability to retrospectively analyze and optimize study design, as well as real-time adaptation during trials.

“Our platform excels at discovering hidden signals in clinical and real-world data, enabling us to analyze a large number of covariates using causal-ML to identify the most beneficial steps and Evaluate subsequent decisions in the clinical development process. and co-founder of PhaseV. “This investment provides us with the resources to further advance our platform and expand our reach to more pharmaceutical, CRO and biotech companies in Europe and the US, bringing much needed new treatments to patients.”

Prilok also addressed the current situation in Israel. Just over two weeks ago, Israel faced an unprecedented terrorist attack and a level of brutality unlike anything we had ever seen before. We debated a lot about whether or not to go out with this announcement, but we decided we weren’t going to let Trevor win. We founded PhaseV to change the world for the better and help one of the most important challenges in drug development – the clinical trial phase. We believe our solution will help bring new medicines and treatments to patients around the world who need them. We must fight the darkness, but we must also spread the light. We choose to continue to spread light in the world. This is our strength.

PhaseV offers two distinct service lines for AI clinical trial optimization. The first involves evaluating the potential impact of the adaptive experimental design on the proposed study, followed by optimal design and implementation. The second involves retrospective analysis that identifies hidden signals in clinical trial data and evaluates endpoints and subpopulations to redefine the success or failure of a trial.

PhaseV was founded by Elad Berkman and Dr. Raviv Pryluk. Prior to founding PhaseV, they managed large multidisciplinary teams at leading technology companies with hands-on experience implementing advanced machine learning, causal inference, and software development at scale. Dr. Dan Goldstubb, who previously managed clinical trials at Teva and MSD, joined the company as a scientific co-founder.

#PhaseV #raises #15M #optimize #clinical #trials #conventional #machine #learning #CTech
Image Source :

Leave a Comment